AC Immune SA income statement

In fiscal 2025, AC Immune SA reported revenue of $4.3m, down 86.1% on the year before, operating income of −$83.7m (a -1940.1% margin) and net income of −$85.0m, or −$0.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AC Immune SA: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	41	24	21	7	111	16	0	4	16	31	4
Research and development	18	26	33	45	51	63	68	63	61	71	68
Operating income	19	−11	−23	−51	45	−65	−86	−74	−60	−59	−84
Interest expense	0	0	0	0	2	—	0	0	0	0	0
Income before tax	21	−7	−27	−52	46	−66	−80	−74	−60	−58	−85
Income tax	0	0	0	0	0	0	0	0	0	0	0
Net income	21	−7	−27	−52	46	−66	−80	−74	−60	−58	−85
Diluted EPS	$0.46	−$0.14	−$0.47	−$0.84	$0.64	−$0.92	−$1.06	−$0.89	−$0.71	−$0.58	−$0.84
Diluted shares (average)	46m	50m	57m	62m	71m	72m	75m	84m	85m	100m	101m

US$ millions unless shown otherwise. Fiscal quarters.

AC Immune SA: income statement, quarterly
Quarter	2017 Q1Mar 2017	2017 Q2Jun 2017	2017 Q3Sept 2017	2017 Q4Dec 2017	2018 Q1Mar 2018	2018 Q2Jun 2018	2018 Q3Sept 2018	2018 Q4Dec 2018
Revenue	2	1	1	17	2	2	2	1
Research and development	7	7	9	10	11	11	12	12
Operating income	−8	−8	−10	3	−12	−12	−12	−15
Income before tax	−9	−13	−9	4	−12	−11	−14	−15
Income tax	0	0	0	0	0	0	0	0
Net income	−9	−13	−9	4	−12	−11	−14	−15
Diluted EPS	−$0.17	−$0.22	−$0.16	$0.07	—	—	—	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACIU vs CRIS ACIU vs CAMP ACIU vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AC Immune SA's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AC Immune SA.